Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5)Homo sapiens (Human)Polyclonal antibody

FRCP2; Irisin; Fibronectin type III repeat-containing protein 2

  • Product No.PAN576Hu01
  • Organism SpeciesHomo sapiens (Human)Same name, Different species.
  • SourcePolyclonal antibody preparation
  • HostRabbit
  • Potencyn/a
  • Ig TypeIgG
  • PurificationAntigen-specific affinity chromatography
  • LabelNone
  • Immunogenn/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid
  • Concentration200ug/ml
  • Organism Species Moren/a
  • ApplicationsWB, ICC, IHC-P, IHC-F, ELISA
  • DownloadInstruction Manual
  • UOM10ug50ug100ug1mg1g
  • FOBUS$ 116US$ 270US$ 386US$ 1544US$ 115800
  • Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5)Package and Components
  • Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5)Package and Components
  • Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5)IHC Images
  • PAN576Hu01.jpgWB Image
  • CertificateISO9001: 2008, ISO13485: 2003 Registered

SPECIFITY

The antibody is a rabbit polyclonal antibody raised against FNDC5. It has been selected for its ability to recognize FNDC5 in immunohistochemical staining and western blotting.

USAGE

Western blotting: 1:50-400
Immunocytochemistry in formalin fixed cells: 1:50-500
Immunohistochemistry in formalin fixed frozen section: 1:50-500
Immunohistochemistry in paraffin section: 1:10-100
Enzyme-linked Immunosorbent Assay: 1:100-1:5000
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Reference

  • Diabetes Research and Clinical PracticeSerum irisin levels in new-onset type 2 diabetesPubMed: 23369227
  • Journal of diabetes and its complicationsLower circulating irisin is associated with type 2 diabetes mellitusPubmed: 23619195
  • Horm Metab Res.Inconsistency in circulating irisin levels: what is really happeningPubmed:24459033
  • Int J Obes (Lond).Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in micePubmed:25199621
  • Molecular and Cellular EndocrinologyFenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese micePubmed:25576856
  • journal of diabetesLower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysisPubMed: 25494632
  • The Journal of Maternal-Fetal & Neonatal MedicineMaternal circulating levels of irisin in intrahepatic cholestasis of pregnancyPubMed: 26689349
  • Hormone and Metabolic ResearchLower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-AnalysisPubmed:27300472